Desloratadine in Patients With Ulcerative Colitis
Recruiting · NCT07333716 · Interventional (participants receive a specific treatment) · Lead sponsor: Tanta University
View the official record on ClinicalTrials.gov →Interventions studied
Desloratadinemesalamine
What this trial is about
The purpose of this study is to investigate safety and therapeutic efficacy of antihistamine (desloratadine) on inflammation and disease activity when administered as adjuvant therapies with the traditional therapy 5-aminosalisylic acid (mesalamine) in patients with mild to moderate ulcerative colitis.
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Both male and female sex.
- patients with age ranged from 18 to 65.
- patients with active mild and moderate ulcerative colitis according to American College of Gastroenterology (ACG) Clinical Guideline.
- Patients treated with 5-aminosalisylic acid (mesalamine).
Exclusion criteria
- Patients with severe UC
- Significant liver or kidney function abnormalities
- Pregnant or lactating females
- Treatment with systemic or rectal steroids
- Treatment with immunosuppressant or biological therapies
- Known allergy to desloratadine or any ingredient in the formulation
- Patients with other inflammatory diseases
- Patients with history of colon cancer
- Patients with complete or partial colectomy
Where it is running
1 location listed.
- Menofia university Hospitals - Shibīn al Kawm, Menofia, Egypt